MTOR and hepatocellular carcinoma: We initially evaluated the simultaneous combination of increasing concentrations of the PI3K/mTOR inhibitors with a fixed concentration of palbociclib (0.5 μM) on MDA-MB-231 (Fig. 4a-c) and HCC-38 cells (Fig. 4d-f).